TL;DR

Leeds Teaching Hospitals NHS Trust has been awarded £1.5 million by the National Institute for Health and Care Research (NIHR) to expand its use of AI in healthcare. The funding will support evaluation of an AI-enabled handheld cardiac ultrasound device for GP surgeries, alongside infrastructure upgrades for developing and validating AI imaging algorithms across a range of major diseases. Implementation is expected to complete by summer 2026.

What the money buys

The flagship element is a point-of-care ultrasound device that uses AI to accelerate heart failure diagnosis directly in primary care. Handheld cardiac ultrasound already exists as a device class, but the AI layer is what turns it from a specialist tool into something a GP or practice nurse can use at first presentation — cutting the typical referral-to-diagnosis wait, which is measured in weeks for suspected heart failure, to a same-appointment decision.

The remaining funding upgrades Leeds’s imaging infrastructure to let researchers train and validate AI diagnostic algorithms on NHS data. That is the less glamorous but arguably more consequential half: building the pipeline that lets clinical AI move from research project to routine tool.

Part of a bigger programme

The Leeds award sits inside a broader £47.8 million NIHR programme aimed at integrating AI into routine clinical practice across UK life sciences. It also lands alongside this week’s MHRA AI Airlock funding expansion and the Oxford heart-failure AI announcement — three pieces of a coordinated UK push to move medical AI from pilot to standard of care. For UK regional hospitals, NIHR’s willingness to fund infrastructure (not just studies) is the meaningful shift: it treats AI readiness as a capital requirement rather than a research add-on.

Looking forward

Leeds is a natural test bed — the trust runs one of the largest teaching hospitals in Europe and has existing AI research links to the University of Leeds. If the handheld ultrasound trial validates at NHS scale, expect the device to feature in future GP contract discussions as a candidate for centrally funded deployment, much as AliveCor ECGs were before it.